The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Mortality Related to Nonalcoholic Fatty Liver Disease Is Increasing in the United States
Open accessAbstract
Population‐level nonalcoholic fatty liver disease (NAFLD) death rate data are sparse. We described death rates for adults with NAFLD in the United States using mortality data from the National Vital Statistics System multiple‐cause mortality data (2007‐2016). Decedents who had NAFLD were identified by International Classification of Diseases (ICD) codes K75.81, K76.0, K74.0, K74.6, and K76.9. Among NAFLD decedents, cause‐specific deaths (e.g., cardiovascular disease [CVD], cirrhosis, hepatocellular carcinoma [HCC], non‐liver cancer, diabetes mellitus [DM]) were identified by underlying cause of death ICD‐10 codes. Trends were evaluated by average annual percentage change (AAPC) in age‐standardized death rate (ASDR) per 100,000 persons. Among the 25,129,960 decedents aged ≥20 years, 353,234 (1.4%) decedents had NAFLD (212,322 men; 260,765 non‐Hispanic whites, 32,868 non‐Hispanic blacks, 46,530 Hispanics, 5,025 non‐Hispanic American Indian or Alaska Natives [AIANs], 7,023 non‐Hispanic Asian or Pacific Islanders [APIs]), with a mean age at death of 64.47 ± 13.17 years. During the study period, the ASDR for NAFLD increased by 15% (12.94 to 14.90; AAPC, 1.98%; P < 0.001]), while women (AAPC, 2.99% vs. 1.16% men; P = 0.003), non‐Hispanic whites (AAPC, 2.48%), non‐Hispanic AIANs (AAPC, 2.31%), and Hispanics (AAPC, 0.74%) experienced the highest annual increases. Stable trends were noted for non‐Hispanic blacks and non‐Hispanic APIs. Among subgroups, Mexican (AAPC, 1.75%) and Asian Indians (AAPC, 6.94%) experienced annual increases. The top six underlying causes of death (155,894 cirrhosis, 38,444 CVD, 19,466 non‐liver cancer, 10,867 HCC, 8,113 DM, and 5,683 lung disease) accounted for 67.5% of NAFLD‐related deaths. For cause‐specific deaths, ASDR increased for HCC (AAPC, 3.82%), DM (AAPC, 2.23%), non‐liver cancer (AAPC, 2.14%), CVD (AAPC, 1.59%), and cirrhosis (AAPC, 0.96%). Conclusion: NAFLD‐related deaths in U.S. adults are increasing. Cirrhosis is the top cause‐specific death, followed by CVD. Women, non‐Hispanic whites, and non‐Hispanic AIANs (subgroups Mexicans and Asian Indians) experienced the highest increases in deaths. Policies addressing the societal burden of NAFLD are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationEkstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287 · cited 3×
“These findings are important, first, because they confirm findings from recent studies that the stage of fibrosis is the independent predictor for death among those with NAFLD/NASH.(29,30) Second, these findings further explain why NAFLD is now the second most common reason for liver transplant and that the rate of li…”
BackgroundResultYounossi, Z. M., Otgonsuren, M., Henry, L., Venkatesan, C., Mishra, A., Erario, M., & Hunt, S. (2015) · Hepatology · doi:10.1002/hep.28123 · Cited by 802 · cited 1×
“(31-35) Third, patients with NASHrelated HCC have a higher rate of mortality following their HCC diagnosis,(36-39) which portends the necessity of developing screening and surveillance guidelines dedicated to patients with NAFLD and fibrosis in hopes of reversing this dismal trend.”
BackgroundSelf-citationGolabi, P., Otgonsuren, M., de Avila, L., Sayiner, M., Rafiq, N., & Younossi, Z. M. (2018) · Medicine · doi:10.1097/md.0000000000010214 · Cited by 221
Self-citation
Cited by
Younossi, Z. M., Golabi, P., Paik, J. M., Henry, A., Van Dongen, C., & Henry, L. (2023) · Hepatology · doi:10.1097/hep.0000000000000004 · Cited by 3,383
Self-citationCusi, K., Isaacs, S., Barb, D., Basu, R., Caprio, S., Garvey, W. T., Kashyap, S., Mechanick, J. I., Mouzaki, M., Nadolsky, K., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.03.010 · Cited by 1,021
Self-citationTargher, G., Byrne, C. D., & Tilg, H. (2020) · Gut · doi:10.1136/gutjnl-2020-320622 · Cited by 827
Paik, J. M., Golabi, P., Younossi, Y., Mishra, A., & Younossi, Z. M. (2020) · Hepatology · doi:10.1002/hep.31173 · Cited by 788
Self-citationMortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort
Simon, T. G., Roelstraete, B., Khalili, H., Hagström, H., & Ludvigsson, J. F. (2021) · Gut · doi:10.1136/gutjnl-2020-322786 · Cited by 673
Younossi, Z. M., Stepanova, M., Ong, J., Trimble, G., AlQahtani, S., Younossi, I., Ahmed, A., Racila, A., & Henry, L. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.05.064 · Cited by 576
Self-citationComplications, morbidity and mortality of nonalcoholic fatty liver disease
Mantovani, A., Scorletti, E., Mosca, A., Alisi, A., Byrne, C. D., & Targher, G. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154170 · Cited by 553
Younossi, Z. M., Corey, K. E., & Lim, J. K. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.11.051 · Cited by 490
Self-citationTherapeutic pipeline in nonalcoholic steatohepatitis
Vuppalanchi, R., Noureddin, M., Alkhouri, N., & Sanyal, A. J. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00408-y · Cited by 278
KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Kang, S. H., Lee, H. W., Yoo, J.-J., Cho, Y., Kim, S. U., Lee, T. H., Jang, B. K., Kim, S. G., Ahn, S. B., Kim, H., et al. (2021) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2021.0178 · Cited by 267
Simon, T. G., Roelstraete, B., Sharma, R., Khalili, H., Hagström, H., & Ludvigsson, J. F. (2021) · Hepatology · doi:10.1002/hep.31845 · Cited by 176
Age and the relative importance of liver-related deaths in nonalcoholic fatty liver disease
Lin, H., Yip, T. C., Zhang, X., Li, G., Tse, Y., Hui, V. W., Liang, L. Y., Lai, J. C., Chan, S. L., Chan, H. L., et al. (2023) · Hepatology · doi:10.1002/hep.32633 · Cited by 52
Community socioeconomic deprivation predicts nonalcoholic steatohepatitis
Giammarino, A. M., Qiu, H., Bulsara, K., Khan, S., Jiang, Y., Da, B. L., Bernstein, D. E., & Satapathy, S. K. (2022) · Hepatology Communications · doi:10.1002/hep4.1831 · Cited by 47
Attaran, F., Emami, S., Sohrabi, M., Malek, M., Ajdarkosh, H., Khoonsari, M., Ismail-Beigi, F., & Khamseh, M. E. (2023) · BMC Gastroenterology · doi:10.1186/s12876-023-02948-4 · Cited by 22
“On the other hand, CVD is a leading cause of mortality among patients with NAFLD, and current evidence suggests that NAFLD is an independent risk factor for CVD [30].”
BackgroundSharma, S., Stine, J. G., Verbeek, T., & Bezinover, D. (2022) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2021.07.020 · Cited by 5
Metadata
- Authors
- Paik, J. M., Henry, L., De Avila, L., Younossi, E., Racila, A., & Younossi, Z. M.
- Venue
- Hepatology Communications
- Published
- 2019-08-14
- Volume
- 3
- Issue
- 11
- Pages
- 1459-1471
- ISSN
- 2471-254X (ISSN-L)
- OpenAlex
- W2968982492
- Cited by
- 225
- References
- 4
- FWCI
- 16.73
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.